Table 1.
Demographic and clinical features of EGFR mutant NSCLC patients according to PNI level and mGPS
| Parameter | PNI | mGPS | |||||
|---|---|---|---|---|---|---|---|
| < 50 | ≥ 50 | P | 0 | 1 | 2 | P | |
| Age (Median, min–max) | 64 (21 – 84) | 62 (32 – 86) | 0.34 | 61(37–83) | 63.5 (32–86) | 67 (21–77) | 0.78 |
| Sex (M/F) (%) | 43.9/56.1 | 43.1/56.9 | 0.92 | 35.3/64.7 | 44.3/55.7 | 70.6/29.7 | 0.40 |
| EGFR Mut | 0.275 | 0.535 | |||||
| Exon 19del | 48.6 | 58.1 | 47.1 | 56.5 | 58.8 | ||
| Exon 21 L858R | 51.4 | 41.9 | 52.9 | 43.5 | 41.2 | ||
| Smoking (%) | 0.60 | 0.59 | |||||
| Active | 10.6 | 8.5 | 7.8 | 8.1 | 17.6 | ||
| Former | 24.2 | 32.2 | 25.5 | 30.6 | 35.5 | ||
| Non-smoker | 65.2 | 59.3 | 66.7 | 61.3 | 47.1 | ||
| ECOG PS (%) | 0.21 | 0.10 | |||||
| 0 | 1.5 | 1.7 | 0 | 3.3 | 0 | ||
| 1 | 46.2 | 66.1 | 58.8 | 55.7 | 58.8 | ||
| 2 | 46.2 | 30.5 | 37.3 | 39.3 | 23.5 | ||
| 3 | 6.1 | 1.7 | 3.9 | 1.6 | 17.6 | ||
| Brain Met (Y/N- %) | 10.6/89.4 | 18.6/81.4 | 0.201 | 17.6/82.4 | 12.9/87.1 | 11.8/88.2 | 0.72 |
| Liver Met (Y/N- %) | 15.2/84.8 | 15.3/84.7 | 0.98 | 15.7/84.3 | 12.9/87.1 | 23.5/76.5 | 0.55 |
| Adrenal Gland Met (Y/N- %) | 27.3/72.7 | 15.3/84.7 | 0.103 | 21.6/78.4 | 21/79 | 29.4/70.6 | 0.75 |
| Lung Met (Y/N- %) | 39.4/60.6 | 54.2/45.8 | 0.097 | 47.1/52.9 | 45.2/54.8 | 41.2/58.8 | 0.91 |
| Bone Met (Y/N- %) | 54.5/45.5 | 40.7/59.3 | 0.121 | 43.1/56.9 | 41.9/58.1 | 58.8/41.2 | 0.44 |
| Pleura Met (Y/N- %) | 45.5/54.5 | 42.4/57.6 | 0.72 | 47.1/52.9 | 50/50 | 41.2/58.8 | 0.8 |
M male, F Female, Met metastasis, ECOG PS Eastern Cooperative Oncology Group Performance score, Y yes, N no, mGPS modified Glasgow prognostic score, PNI Prognostic nutritional index, Mut mutation, mGPS Modified Glasgow prognostic score